Keyphrases
Breast Tumor
100%
Tumor Antigen
100%
Neoepitope
100%
Janus Kinase 2 (JAK2)
76%
Triple-negative Breast Cancer
69%
Breast Cancer
69%
TPD52
61%
Tumor Protein p53 (TP53)
61%
PIK3CA
61%
HLA-A
53%
Immunogenic
46%
T Cell Epitope
46%
Somatic mutation
46%
T Cell Immunity
38%
Immunogenicity
38%
Programmed Death-ligand 1 (PD-L1)
30%
Specific Intent
30%
Epitope
30%
Tumor
30%
Uncommon mutation
23%
Immunogenic Epitopes
23%
Breast Cancer Vaccine
23%
Vaccine Development
23%
Specific Immunity
23%
HLA Class I
23%
SABCS
15%
PD-L2
15%
ELISPOT
15%
HLA Binding
15%
Interferon-α (IFN-α)
15%
Array Comparative Genomic Hybridization (aCGH)
15%
Integrated Bioinformatics Analysis
15%
In Cancer
15%
Mutation Specific
15%
Checkpoint Blockade
15%
Biochemical Verification
15%
Antigenic Peptide
15%
K562
15%
Mathematical Model
15%
Breast Cancer Patients
15%
Hydro
15%
HLA-B
15%
Amplicon
15%
HLA-B*15
7%
HLA-A*03
7%
Dynamic Regulation
7%
Anti-CTLA-4
7%
Peptide-based
7%
Multimer Analysis
7%
Specific Immune Response
7%
Immunomics
7%
Cancer 2
7%
R175H
7%
HLA Class I Molecules
7%
Non-immunogenic
7%
PD-L1 Expression
7%
Rational Vaccine Design
7%
Class I Alleles
7%
Potential Vaccine Candidate
7%
Antigen Discovery
7%
H1047R
7%
Supertype
7%
Leave-one-out
7%
Null Cell
7%
Self-assembling Peptide
7%
Model Antigen
7%
HLA-A*02
7%
High-level Amplifications
7%
Term Expansion
7%
Colon
7%
Peripheral Blood
7%
Antigen Processing
7%
Cross-validation Analysis
7%
NetMHCpan
7%
HLA Restriction
7%
Preclinical Data
7%
Anti-PD-1
7%
Selective Detection
7%
Exome-seq
7%
Gene TP53
7%
HLA-B*57
7%
T Cell Specificity
7%
Multiple Epitopes
7%
Target Epitope
7%
HLA Matching
7%
Algorithm Strategy
7%
Top 50
7%
PD-L1 Amplification
7%
NetMHC
7%
Human Epidermal Growth Factor Receptor 2 (HER2)
7%
HLA-B27
7%
Vesicle Trafficking
7%
FISH Probes
7%
Vaccine Target
7%
METABRIC
7%
Existing Data
7%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
7%
Positive Responses
7%
Mutated Antigen
7%
IC50
7%
Breast Cancer Genomics
7%
Breast Cancer Cell Lines
7%
Poor Prognosis
7%
R273H
7%
Predictive Biomarker
7%
Prediction Algorithms
7%
Genetic Drivers
7%
Copy number
7%
Prediction Model
7%
Proteome
7%
HLA-DR
7%
Arizona
7%
Potential Analysis
7%
Advanced Triple-negative Breast Cancer
7%
Binding Affinity
7%
Most Common Form
7%
Artificial Neural Network (ANN) Model
7%
TP53 mutation
7%
Hydrophobicity
7%
Mathematical Modeling
7%
Mortality Rate
7%
Mass Spectrometry
7%
Immune Monitoring
7%
Cancer-specific
7%
Specific T Cells
7%
Clinical Trials
7%
Healthy Donors
7%
CD8+ T Cells
7%
Cell Proliferation
7%
PIK3CA mutation
7%
Lung
7%
Biomarkers of Response
7%
Overall Response Rate
7%
Y220C
7%
Tumor Heterogeneity
7%
Prostate Cancer
7%
RNA Sequencing (RNA-seq)
7%
Anti-PD-1 Therapy
7%
Barrett
7%
Gene Regulation
7%
Targeted Immunotherapy
7%
Proteomics
7%
Optimal Target
7%
Data Identification
7%
Rate-limiting Step
7%
Cellular Immune Response
7%
Cancer Vaccine
7%
RNA Expression
7%
Target Antigen
7%
Immunome
7%
Mayo Clinic
7%
Adjuvant Therapy
7%
Predictive Models
7%
Immune System
7%
Signal Transduction
7%
Ovarian Cancer
7%
Breast Cancer Susceptibility Gene 1 (BRCA1)
7%
Recurring
7%
Bioinformatics
7%
Minimal Residual Disease
7%
Medicine and Dentistry
Tumor Antigen
100%
Immunotherapy
100%
Epitope
100%
Breast Cancer
100%
Triple Negative Breast Cancer
42%
Janus Kinase
38%
HLA-A
34%
T Cell
26%
Programmed Death-Ligand 1
23%
Cellular Immunity
23%
Somatic Mutation
23%
Immunogenicity
19%
In Vitro
15%
Tumor Vaccine
15%
Neoplasm
15%
Allele
11%
Adaptive Immunity
11%
Vaccine Development
11%
Array Comparative Genomic Hybridization
7%
Enzyme Linked Immunospot Assay
7%
Interferon
7%
Amplicon
7%
Malignant Neoplasm
7%
Immunology and Microbiology
Immunotherapy
100%
Epitope
100%
Tumor Antigen
100%
Peptides
42%
T Cell
26%
Somatic Mutation
23%
Programmed Death-Ligand 1
23%
Adoptive Immunity
23%
Immunogenicity
19%
Tumor Vaccine
15%
HLA A11 Antigen
11%
Allele
11%
Bioinformatics
11%
Adaptive Immune System
11%
Artificial Neural Network
11%
Array Comparative Genomic Hybridization
7%
interferon
7%
Amplicon
7%
ELISPOT
7%